Abstract
Background: Hepatotoxicity is a common side effect of pyrazinamide, a first line anti-tuberculous drug. Objective of this study was to determine the hepatoprotective effect of zinc complex of Betulinic acid (BA) on pyrazinamide induced hepatotoxicity in mice. Methods: This experimental, randomized control study was conducted at Islamic International Medical College, Rawalpindi, and National Institute of Health Islamabad from 1 Sep 2020 to 31 Aug 2021. Thirty male Balb/c albino mice were divided into three groups each having 10 mice. Group 1 received normal diet with no medication. Group 2 (NC) received pyrazinamide 500 mg/Kg daily for 28 days. Group 3 (DC) received Zinc complex of Betulinic acid 1 mg/Kg/day per oral once daily along with pyrazinamide. Final sampling was done on day 28 by intracardiac puncture for estimation of serum ALT and bilirubin level. Data was analysed on SPSS-21. Comparisons between the groups were analyzed using one way ANOVA (Post Hoc Tuckey test), and p<0.05 was considered significant. Results: Zinc complex of Betulinic acid treated group had significantly decreased serum ALT (58.00±5.639) and bilirubin (0.617±0.601) in comparison with pyrazinamide treated group. Conclusion: Zinc complex of Betulinic acid exerted significant hepatoprotective activity in pyrazinamide induced hepatotoxicity. Pak J Physiol 2023;19(3):36–8
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
